CD19 vs BCMA vs GPRC5D:
WHAT THESE CAR-T TARGETS MEAN
A CAR-T product is defined by what it points at. Understanding the target tells you which cancer it treats, who qualifies, and why some patients respond and others relapse.
analyticsAt a Glance
- check_circleCD19 is expressed on all B cells — the universal target for B-cell lymphoma and B-cell ALL CAR-T products
- check_circleBCMA (B cell maturation antigen) is expressed on plasma cells — the primary target for multiple myeloma CAR-T
- check_circleGPRC5D is a newer myeloma target that enables retreatment when BCMA-directed CAR-T has failed
- check_circleChina's NMPA has approved CAR-T products against all three targets — with broader indications than FDA/EMA in some areas
What Is a CAR-T Target Antigen and Why Does It Matter?
A chimeric antigen receptor T cell (CAR-T) is an immune cell engineered to express a synthetic receptor that recognises a specific protein on the surface of cancer cells. That protein is the target antigen — and the choice of target determines everything about the product: which cancers it can treat, which patients are eligible, how it distinguishes cancer cells from normal cells, and why some patients eventually relapse through antigen loss.
“Choose the wrong target and the CAR-T cells have nothing to bind. Choose the right target and you give the immune system a lock to match its key.”
What Makes a Good CAR-T Target
An ideal target antigen is: expressed on all or most cancer cells (high density); absent or minimally expressed on critical normal tissues (tumour selectivity); not shed into the blood in large quantities (stable surface expression); and not easily downregulated by the tumour under immune pressure. No target fully meets all criteria — the clinical trade-offs define each product's profile.
Antigen Loss: The Relapse Mechanism
One of the most common mechanisms of resistance to CAR-T therapy is antigen loss or downregulation — the tumour stops expressing the targeted protein, making the CAR-T cells ineffective. CD19-negative relapse occurs in 20–40% of patients after CD19-directed CAR-T. Dual-target products (CD19+CD22, BCMA+CD19) and sequential different-target treatment address this problem.
CD19, BCMA, and GPRC5D: Side-by-Side Comparison
A direct comparison of the three principal CAR-T target antigens — covering biology, cancer indication, approved products, response rates, and the key clinical trade-off for each.
| Feature | CD19 | BCMA | GPRC5D |
|---|---|---|---|
| Normal cell expression | All B lymphocytes (mature and immature) | Plasma cells and some B cell subsets | Hair follicles, some epithelial cells; lower critical organ expression than BCMA |
| Cancer target | B-cell NHL (DLBCL, FL, MCL, PMBCL), B-cell ALL | Multiple myeloma (plasma cell origin) | Multiple myeloma — especially post-BCMA failure |
| On-target off-tumour toxicity | B cell aplasia (lifelong if not reconstituted) — manageable with Ig replacement | Manageable — cytopenias, infections | Nail/hair changes, dysgeusia (taste change) — distinct toxicity profile from BCMA |
| Global FDA-approved products | Axicabtagene, tisagenlecleucel, lisocabtagene | Idecabtagene vicleucel (Abecma), ciltacabtagene (Carvykti) | Talquetamab (not CAR-T but bispecific); CAR-T: investigational only |
| China NMPA-approved products | Relma-cel (relmacabtagene), lisocabtagene, equecabtagene (anti-BCMA+CD19 dual) | Relmacabtagene autoleucel (equecabtagene), CT053, satricabtagene | GPRC5D-directed products in advanced Chinese trials; some approved 2024 |
| Best response rate (CR) | 40–60% CR in 3L+ DLBCL; 60–80% in r/r B-ALL | 60–80% ORR; 30–45% sCR in 3L+ myeloma | ~70–80% ORR in post-BCMA myeloma — promising early data |
| Key relapse mechanism | CD19 antigen loss (20–40%) | BCMA antigen loss or downregulation | GPRC5D loss less common in early data — potentially more stable expression |
| Position in treatment sequence | 3L+ standard; 2L approved for early-relapsed DLBCL (ZUMA-7) | 4L+ standard; moving to earlier lines in trials | Post-BCMA failure — important salvage option when BCMA CAR-T has been used |
Key Clinical Numbers by Target
Response rate benchmarks for each principal target from pivotal approval trials and large published series.
- 52%Complete response rate — axicabtagene ciloleucel in 3L+ DLBCL (ZUMA-1)The ZUMA-1 pivotal trial showed 52% CR rate with axi-cel in relapsed/refractory DLBCL after ≥2 prior lines — the data that led to the first lymphoma CAR-T approval. Long-term follow-up shows ~40% of CR patients remain in remission at 4 years.
- 98%ORR for ciltacabtagene autoleucel in r/r myeloma (CARTITUDE-1)The CARTITUDE-1 trial of cilta-cel (BCMA-directed, NMPA and FDA approved) achieved 98% ORR with 78% sCR in heavily pre-treated myeloma — the highest complete remission rate of any approved myeloma therapy.
- 84%ORR in post-BCMA-failure myeloma with GPRC5D-directed CAR-T (early Chinese series)Early Chinese clinical series of GPRC5D-directed CAR-T products in patients who have previously received BCMA-targeted therapy show ORR of approximately 80–85% — demonstrating activity in one of the most challenging myeloma treatment scenarios.
How to Think About Target Selection in Your Treatment Planning
For patients considering CAR-T therapy, understanding which target is relevant to your diagnosis — and which products are available against it — is the foundation of an eligibility assessment.
- 1
Confirm Your Diagnosis and Cell Type
CD19-directed CAR-T is for B-cell malignancies — DLBCL, follicular lymphoma, mantle cell lymphoma, B-cell ALL. If your diagnosis is T-cell lymphoma, multiple myeloma, or a myeloid malignancy, CD19-directed products are not indicated. Confirm cell lineage from your pathology report before exploring CD19 options.
- 2
For Myeloma: Establish Prior BCMA Exposure
If you have received a BCMA-directed therapy (either CAR-T or a BCMA bispecific antibody), GPRC5D-directed products are the next consideration. The sequence matters: BCMA first (ciltacabtagene, equecabtagene) → GPRC5D after BCMA failure. Dual-targeted products (BCMA+CD38, BCMA+GPRC5D) are also in active trials.
- 3
Check Antigen Expression if Doubt Exists
For BCMA-directed products, BCMA expression on plasma cells should be confirmed by IHC or flow cytometry from a recent bone marrow biopsy. Very low BCMA expression may reduce response probability. GPRC5D expression testing is less standardised — most trials enrol without mandatory GPRC5D testing.
- 4
Map Against China's Broader Approval Portfolio
China's NMPA has approved more CAR-T products than FDA or EMA — including dual-targeted BCMA+CD19 products and GPRC5D-directed constructs not yet approved elsewhere. If you are ineligible for products available in your home country, a Chinese-approved product may provide access. CancerFax maps your profile against the full NMPA-approved portfolio.
- 5
Consider Investigational Targets for Refractory Cases
CD22, CD38, CD138, FcRH5, and SLAMF7 are additional myeloma and lymphoma targets under investigation in Chinese and international trials. For patients who have exhausted approved targets, clinical trial matching against these emerging targets is the appropriate next step.
CD19 CAR-T vs BCMA CAR-T: Clinical Differences That Matter
While CD19 and BCMA target different diseases (lymphoma/ALL vs myeloma), understanding their distinct clinical profiles helps patients and families navigate discussions with their haematologist.
CD19-Directed CAR-T
- Target disease: B-cell NHL and ALLCD19 is expressed on all B cells from the pro-B cell stage through mature B cells — making it the universal target for B-cell lymphomas (DLBCL, FL, MCL) and B-cell acute lymphoblastic leukaemia.
- On-target toxicity: B cell aplasiaBecause CD19 is on all normal B cells, CD19-directed CAR-T eliminates normal B cells alongside tumour cells. This causes hypogammaglobulinaemia (low immunoglobulins) requiring IVIG replacement — manageable but lifelong in long-term responders.
- Resistance: CD19-negative relapse in 20–40%The most important relapse mechanism — tumour cells downregulate or lose CD19 expression. Biopsy at relapse is essential to confirm whether CD19-negative escape has occurred.
BCMA-Directed CAR-T
- Target disease: multiple myeloma (plasma cells)BCMA (B cell maturation antigen, TNFRSF17) is highly expressed on normal and malignant plasma cells — making it the primary target for myeloma CAR-T therapy.
- On-target toxicity: manageable; less B cell aplasiaBCMA is expressed on plasma cells, not mature B cells — so B cell aplasia is less prominent. Main toxicities are cytopenias, infections, and the neurotoxicity profile shared with other T cell-based therapies.
- Resistance: BCMA downregulation — GPRC5D becomes next optionBCMA loss or downregulation occurs after BCMA-directed therapy — whether CAR-T or bispecific antibody. GPRC5D-directed therapy is the established next step when BCMA expression is lost or disease progresses.
Frequently Asked Questions
Common questions about CAR-T target antigens from patients and families.
About CAR-T Targets
Can I receive CD19 CAR-T if I have already had rituximab (anti-CD20)?
Yes — rituximab targets CD20, not CD19. Prior rituximab does not affect CD19 expression or CD19-directed CAR-T eligibility. In fact, most patients eligible for CD19 CAR-T have received prior rituximab-containing regimens as part of their first-line treatment. CD19 expression should be confirmed on a recent biopsy, as rare CD19-negative tumour escape can occur after other anti-B cell therapies.
What is the difference between BCMA CAR-T and BCMA bispecific antibodies?
Both target BCMA but via different mechanisms. CAR-T cells are a living, potentially self-renewing cell product that is infused once (sometimes twice) and may persist for years. BCMA bispecific antibodies (teclistamab, elranatamab) are a repeatedly dosed drug that engages the patient's endogenous T cells at the tumour site without cell manufacturing. CAR-T tends to produce deeper remissions; bispecifics are more immediately accessible and can be given continuously. Patients who fail BCMA bispecifics may still respond to BCMA CAR-T and vice versa.
Is GPRC5D CAR-T available outside clinical trials?
As of 2024–2025, GPRC5D-directed CAR-T products are commercially approved in China (NMPA) and are in late-stage trials internationally. FDA and EMA approval for GPRC5D CAR-T is anticipated in 2025–2026. For patients outside China who need GPRC5D-directed therapy now, Chinese clinical trial enrolment or named-patient access through CancerFax is the current pathway.
My myeloma has relapsed after ciltacabtagene (BCMA CAR-T) — what are my options?
This is one of the most important clinical questions in myeloma today. Options include: GPRC5D-directed CAR-T (if BCMA expression has been lost or is low); other non-BCMA targets (CD138, FcRH5, SLAMF7) available in trials; BCMA bispecific antibodies (if prior BCMA CAR-T failure does not preclude response — some patients respond); and conventional salvage with daratumumab or carfilzomib-based combinations. CancerFax can map your residual options against your complete treatment history and current molecular profile.
More from the CAR-T Cell Therapy Resource Library
Continue exploring CAR-T therapy guides — from China's approved products to disease-specific eligibility.
- ↑ CAR-T Cell Therapy — Complete Guide
- China's Four Approved CAR-T Products
- CAR-T for DLBCL in China: Eligibility and Outcomes
- Second-Line CAR-T for Early-Relapsed DLBCL: ZUMA-7 Explained
- CAR-T for Relapsed/Refractory B-Cell ALL in China
- Second Opinions for CAR-T Therapy Eligibility: China vs Western Access
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Find Out Which CAR-T Target Is Relevant to Your Diagnosis
CancerFax reviews your diagnosis, molecular profile, and treatment history to map eligibility against currently approved and investigational CAR-T products — including Chinese NMPA-approved constructs not available elsewhere.
This content is for informational purposes only and does not constitute medical advice. CAR-T eligibility must be assessed by a qualified haematologist.